Company Financials

Ligand Pharmaceuticals Incorporated Financials

United States dollar

business Ligand Pharmaceuticals Incorporated Company Profile

Main Stock Listing

NASDAQ: LGND

Market Capitalization $3.74 Billion as of Jan. 1, 2026

Market Cap History

Valuations Metrics as of Jan. 3, 2026

Trailing PE 84.12
Forward PE 22.59
Price to Sales TTM $14.89
Price to Book MRQ $3.93
Enterprise to Revenue 14.04
Enterprise to EBITDA 55.97

Financial Reports as of Sep. 30, 2025

Financials

Fiscal Year Ends 2024-12-31
Most Recent Quarter 2025-09-30
Profit Margin 19.34%
Operating Margin 46.85%
Return on Assets TTM 1.48%
Return on Equity TTM 5.42%

Income Statement

Revenue TTM $251,232,992
Revenue per Share TTM $13.04
Quarterly Revenue Growth 122.80%
Gross Profit TTM $154,743,008
EBITDA $11,397,000
Net Income to Common TTM $48,581,000
Diluted EPS TTM $2.26
Quarterly Earnings Growth YoY 122.85%

Balance Sheet

Total Cash MRQ $664,521,984
Total Cash per Share MRQ $33.76
Total Debt MRQ $
Total Debt to Equity MRQ 47.47
Current Ratio MRQ 24.69
Book Value per Share MRQ $48.34

Cash Flow

Operating Cash Flow TTM $31,915,000
Levered Free Cash Flow TTM $97,809,624

LGND Stock Info as of Jan. 3, 2026

Stock Statistics

Shares Outstanding 19,656,000
Float Shares 19,256,201
Avg 10 Volume 170,309
Avg 30 Volume None
Shares Short 1,095,980
Short Ratio 4.72
Short % of Shares 6.72%
% Held by Insiders 2.26%
% Held by Institutions 106.69%

Stock Price Summary

Beta 0.86
Fifty Two Week Low $93.58
Fifty Two Week High $212.49
Fifty Two Week Change 43.23%
Day 50 MA $195.07
Day 200 MA $147.61

Dividends and Splits

Forward Annual Dividend Rate $
Forward Annual Dividend Yield %
Trailing Annual Dividend Rate $0.00
Trailing Annual Dividend Yield 0.00%
Payout Ratio 0.00%
Dividend Date
Ex Dividend Date 2010-07-02
Last Split Factor
Last Split Date 2022-11-02